(Q38074885)

28 August 2017

1 reference

title

Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future (English)

1 reference

28 August 2017

Philippe Fournier

1

1 reference

28 August 2017

Volker Schirrmacher

series ordinal

2

1 reference

28 August 2017

publication date

1 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

27

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

35-53

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

New antibody drug treatments for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Antibodies to watch in 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Molecular engineering and design of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Bispecific antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Hybrid antibodies can target sites for attack by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

A revival of bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Bispecific antibody conjugates in therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Bispecific antibodies for cancer immunotherapy: Current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Complement function in mAb-mediated cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Glycosylation of recombinant antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Intracellular functions of N-linked glycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Fc receptors are required in passive and active immunity to melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

21 January 2018

IgG4 breaking the rules

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised inE. coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Intracellular and cell surface displayed single-chain diabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Strategies to extend plasma half-lives of recombinant antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

An efficient route to human bispecific IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

A modular IgG-scFv bispecific antibody topology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Recombinant bispecific antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

BiTEs: bispecific antibody constructs with unique anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Cancer immunotherapy: a treatment for the masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Natural killer cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Engineered therapeutic antibodies with improved effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

When binding is enough: nonactivating antibody formats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Interaction sites on human IgG-Fc for FcgammaR: current models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

The impact of glycosylation on the biological function and structure of human immunoglobulins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Making autoantibodies safe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

The new face of bispecific antibodies: targeting cancer and much more

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Bispecific antibodies engage T cells for antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Naptumomab estafenatox: a new immunoconjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0008-Z

10.1007/S40259-012-0008-Z

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference